Cancer

Theralase(R) Launches Three New Clinical Study Sites in USA

Associated Medical Professionals of NY, Urology of Indiana and Central Ohio Urology Group are the latest three US-based study sites…

1 year ago

Sunshine Biopharma Announces Novel Inhibitor for Sars Coronavirus

FORT LAUDERDALE, FL / ACCESSWIRE / December 9, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering…

1 year ago

Sonnet BioTherapeutics Announces Topline Safety Data Following Successful Completion of SON-1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial

The maximum tolerated dose (MTD) of SON-1010 was set at 1200 ng/kg, without dose-limiting toxicity or evidence of cytokine release…

1 year ago

SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML

- Median Overall Survival (mOS) Not Yet Reached, Now Exceeds 7.7. Months at Latest Follow-Up in the 30 mg BIW…

1 year ago

Achieve Life Sciences Appoints Mark Oki as Chief Financial Officer

SEATTLE and VANCOUVER, British Columbia, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical…

1 year ago

NCCN Prostate Cancer Guidelines Reinforce Status of Myriad Genetics’ Prolaris® Test as an ‘Advanced Tool’ Recommended for Prognostic Assessment

Prolaris Remains a Long-Standing Fixture in the Guidelines for 10th Year RunningSALT LAKE CITY, Dec. 09, 2024 (GLOBE NEWSWIRE) --…

1 year ago

Mestag Therapeutics Announces Licensing of a Novel Inflammatory Disease Target from its RAFT Platform

CAMBRIDGE, United Kingdom, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Mestag Therapeutics (“Mestag”), a biotech company harnessing new insights into fibroblast-immune…

1 year ago

Evaxion announces 2025 milestones reflecting continued strong strategy execution

With most of Evaxion’s strategic milestones for 2024 now successfully achieved, the company announces milestones for 2025The 2025 key milestones…

1 year ago

Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design

Preliminary data suggests improved relapse-free survival compared to published groups of acute myeloid leukemia (AML) patients at high risk of…

1 year ago

Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer

No dose-limiting toxicities reported in two different weekly doses in heavily pre-treated patients Preliminary evidence of dose response includes significant…

1 year ago